Literature DB >> 12039897

Resistance of Helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicillin and cefixime.

Zmira Samra1, Haim Shmuely, Yaron Niv, Gabriel Dinari, Douglas J Passaro, Alex Geler, Eyal Gal, Michal Fishman, Jacklin Bachor, Jacob Yahav.   

Abstract

The resistance of Helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicillin and cefixime was tested in 138 isolates, including 28 from treatment failures. No resistance to tetracycline was detected. Resistance to amoxicillin was found in one isolate (MIC = 1.5 mg/L) from an untreated patient, and resistance to cefixime in two isolates from each group (P = 0.18). Resistance to metronidazole and clarithromycin was much higher in the isolates from treated than from untreated patients: 60.7% and 38.2% for metronidazole (MIC >or= 8 mg/L) (P = 0.03); 46.4% and 8.2% for clarithromycin (MIC >or= 2 mg/L) (P < 0.001). Therapeutic outcome would benefit from susceptibility testing, especially after treatment failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12039897     DOI: 10.1093/jac/dkf041

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

Review 1.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  13C-urea breath test for success of Helicobacter pylori eradication: study of 5885 Israeli patients.

Authors:  Y Niv; R Koren
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

3.  Integrative computational protocol for the discovery of inhibitors of the Helicobacter pylori nickel response regulator (NikR).

Authors:  Aldo Segura-Cabrera; Xianwu Guo; Arturo Rojo-Domínguez; Mario A Rodríguez-Pérez
Journal:  J Mol Model       Date:  2011-03-01       Impact factor: 1.810

4.  16S rRNA mutations that confer tetracycline resistance in Helicobacter pylori decrease drug binding in Escherichia coli ribosomes.

Authors:  Lisa Nonaka; Sean R Connell; Diane E Taylor
Journal:  J Bacteriol       Date:  2005-06       Impact factor: 3.490

5.  Trends in secondary antibiotic resistance of Helicobacter pylori from 2007 to 2014: has the tide turned?

Authors:  Doron Boltin; Haim Ben-Zvi; Tsachi Tsadok Perets; Zvi Kamenetsky; Zmira Samra; Ram Dickman; Yaron Niv
Journal:  J Clin Microbiol       Date:  2014-11-26       Impact factor: 5.948

6.  13C-urea breath test for diagnosis of Helicobacter pylori infection in the elderly.

Authors:  Yaron Niv; Galia Niv; Rivka Koren
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

7.  Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.

Authors:  Wei Fu; Zhiqiang Song; Liya Zhou; Yan Xue; Yu Ding; Baojun Suo; Xueli Tian; Li Wang
Journal:  Dig Dis Sci       Date:  2017-04-08       Impact factor: 3.199

8.  Universal high-level primary metronidazole resistance in Helicobacter pylori isolated from children in Egypt.

Authors:  May Sherif; Zaynab Mohran; Hanan Fathy; David M Rockabrand; Patrick J Rozmajzl; Robert W Frenck
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

9.  Incidence of Helicobacter pylori infection and their clarithromycin-resistant strains in otitis media with effusion regarding phenotypic and genotypic studies.

Authors:  Nahla A Melake; Ghada H Shaker; Magdy A Salama
Journal:  Saudi Pharm J       Date:  2012-03-03       Impact factor: 4.330

10.  Susceptibility-guided vs. empiric retreatment of Helicobacter pylori infection after treatment failure.

Authors:  Jacob Yahav; Zmira Samra; Yaron Niv; Charlesnika T Evans; Douglas J Passaro; Gabriel Dinari; Haim Shmuely
Journal:  Dig Dis Sci       Date:  2006-11-01       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.